-
0
global
1
1.0
9
1.0
2
1.0
3
1.0
1.0
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Are you looking to get up to speed about emerging research on ctDNA, systemic therapy, and managing toxicity in early-stage triple negative breast cancer? Learn more here.
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Advanced and Metastatic Breast Cancer
846
global
1
1.25
9
1.25
2
1.25
3
1.25
1.25
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Are you up to date on the latest data regarding metastatic HER2-positive breast cancer?
1.25ABIM MOC
1.25CME/CE
75MIN
Save
-
Breast Cancer
840
global
1
1.5
9
1.5
2
1.5
3
1.5
1.5
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Top breast cancer experts cover the latest data on brain metastases in breast cancer, HER2-low breast cancer and HER2 testing.
1.5ABIM MOC
1.5CME/CE
90MIN
Save
-
Peripheral Artery Disease
419
global
1
0.25
9
0.25
0.25
Commentary
0
1
Cardiology2022-11-30 19:00:00
Would you like to know more about assessing and screening the right patients for peripheral artery disease?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Breast Cancer
840
global
1
1.5
9
1.5
2
1.5
3
1.5
1.5
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Did you know that approximately 65% to 70% of all breast cancers express hormone receptors in the absence of HER2 amplification?
1.5ABIM MOC
1.5CME/CE
90MIN
Save
-
Basal Cell Carcinoma
59
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Dermatology2022-11-29 19:00:00
How do you handle patients with basal cell carcinoma (BCC) when surgery isn’t the best option?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
0
global
1
1.0
9
1.0
2
1.0
3
1.0
1.0
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Are you looking to get up to speed about emerging research on ctDNA, systemic therapy, and managing toxicity in early-stage triple negative breast cancer? Learn more here.
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Advanced and Metastatic Breast Cancer
846
global
1
1.25
9
1.25
2
1.25
3
1.25
1.25
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Are you up to date on the latest data regarding metastatic HER2-positive breast cancer?
1.25ABIM MOC
1.25CME/CE
75MIN
Save
-
Breast Cancer
840
global
1
1.5
9
1.5
2
1.5
3
1.5
1.5
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Top breast cancer experts cover the latest data on brain metastases in breast cancer, HER2-low breast cancer and HER2 testing.
1.5ABIM MOC
1.5CME/CE
90MIN
Save
-
Peripheral Artery Disease
419
global
1
0.25
9
0.25
0.25
Commentary
0
1
Cardiology2022-11-30 19:00:00
Would you like to know more about assessing and screening the right patients for peripheral artery disease?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Breast Cancer
840
global
1
1.5
9
1.5
2
1.5
3
1.5
1.5
Roundtable
0
1
Hematology-Oncology2022-11-30 19:00:00
Did you know that approximately 65% to 70% of all breast cancers express hormone receptors in the absence of HER2 amplification?
1.5ABIM MOC
1.5CME/CE
90MIN
Save
-
Basal Cell Carcinoma
59
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Dermatology2022-11-29 19:00:00
How do you handle patients with basal cell carcinoma (BCC) when surgery isn’t the best option?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Breast Cancer
840
global
1
1.75
9
1.75
2
1.75
3
1.75
1.75
Roundtable
0
1
Hematology-Oncology2022-11-29 19:00:00
Did you know that about 20% of HR-positive HER2-negative EBCs are primary endocrine therapy-resistant and have high risk of early recurrence?
1.75ABIM MOC
1.75CME/CE
105MIN
Save
-
Skin Cancer
56
global
1
1.0
9
1.0
2
1.0
1.0
Roundtable
0
1
Dermatology2022-11-28 19:00:00
Is sunscreen and annual skin cancer screening for everyone? Is gene expression profile (GEP) of clinical use in skin cancer patients?
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Advanced and Metastatic Breast Cancer
846
global
1
1.5
9
1.5
2
1.5
3
1.5
1.5
Roundtable
0
1
Hematology-Oncology2022-11-28 19:00:00
Did you know that ribociclib and abemaciclib are 4- and 5-times more selective toward CDK4 over CDK6?
1.5ABIM MOC
1.5CME/CE
90MIN
Save
-
Cardiomyopathy
342
global
1
1.0
9
1.0
1.0
Roundtable
0
1
Cardiology2022-11-27 19:00:00
Are you familiar with the latest cardiac myosin inhibitors and how they may help your patients with hypertrophic cardiomyopathy (HCM)?
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Breast Cancer
840
global
1
0.5
2
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-11-27 19:00:00
Do you know how best to discuss risk of recurrence and treatment approaches with patients? Can you effectively educate patients on potential adverse events (AEs)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Breast Cancer
840
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-11-27 19:00:00
How confident are you at identifying patients with hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Obesity
3032356
global
1
0.25
9
0.25
2
0.25
8
0.25
0.25
Clinical Brief
0
1
Ob/Gyn & Women's Health2022-11-22 19:00:00
Personalized risk estimates can inform clinical decision-making for women with benign conditions who may require a hysterectomy.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Arthroplasty
64500
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Orthopaedics2022-11-16 19:00:00
Prosthetic joint infections (PJIs) are a source of significant morbidity and can be fatal if missed. Are you up to date on new diagnostic technologies?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Peripheral Artery Disease
419
global
1
0.75
0.75
Roundtable
0
1
Cardiology2022-11-16 19:00:00
Are your patients with peripheral artery disease (PAD) on dual pathway inhibition? Listen as our experts discuss the latest data on this new treatment strategy.
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Melanoma
65
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-11-14 19:00:00
Are you up to date on treatment strategies using immunotherapy for managing the whole spectrum of melanoma?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Melanoma
65
global
1
0.5
9
0.5
2
0.5
3
0.5
0.5
Roundtable
0
1
Hematology-Oncology2022-11-13 19:00:00
Dr Atkins provides a comprehensive summary on the treatment landscape for patients with BRAF-mutant metastatic melanoma.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-11-07 19:00:00
Did you know that bladder cancer is highly treatable in the localized stages? Learn more about the latest in treating early-stage bladder cancer.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
